[ALXN] Alexion Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 28.04 B

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 127.19 Change: 1.34 (1.06%)
Ext. hours: Change: 0 (0%)

chart ALXN

Refresh chart

Strongest Trends Summary For ALXN

ALXN is in the long-term up 2384% in 26 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is

Fundamental Ratios
Shares Outstanding224.02 M EPS3.07 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 17.14% Sales Growth - Q/Q0.14% P/E37.13
P/E To EPS Growth P/S12.36 P/BV7.97 Price/Cash Per Share14.56
Price/Free Cash Flow55.69 ROA13.34% ROE16.74% ROI15.36%
Current Ratio4.92 Quick Ratio4.61 Long Term Debt/Equity0.05 Debt Ratio0.17
Gross Margin90.72% Operating Margin33.65% Net Profit Margin25.97% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities5.07 M Cash From Investing Activities-48.42 M Cash From Operating Activities23.03 M Gross Profit584.2 M
Net Profit170.22 M Operating Profit181.08 M Total Assets13.17 B Total Current Assets2.53 B
Total Current Liabilities769.17 M Total Debt3.5 B Total Liabilities4.61 B Total Revenue636.21 M
Technical Data
High 52 week141.3 Low 52 week93.94 Last close130.9 Last change-0.38%
RSI41.11 Average true range3.76 Beta1.14 Volume2.37 M
Simple moving average 20 days-1.22% Simple moving average 50 days-2.32% Simple moving average 200 days5.77%
Performance Data
Performance Week-0.6% Performance Month3.96% Performance Quart1.14% Performance Half10.45%
Performance Year9.39% Performance Year-to-date34.45% Volatility daily1.92% Volatility weekly4.28%
Volatility monthly8.78% Volatility yearly30.41% Relative Volume244.27% Average Volume1.33 M
New High New Low

News

2019-11-12 11:37:00 | Buy Big Biotech — But Not Gilead, Analyst Says

2019-11-11 12:51:49 | Drugmaker Amgen cuts a quarter of its Kendall Square research staff

2019-11-11 09:15:02 | Celgene CELG Hits 52-Week High, Can the Run Continue?

2019-11-08 08:00:01 | Pharma Sector Tops in October: Best ETFs & Stocks

2019-11-06 10:30:00 | Alexion Announces Data Presentations at 61st American Society of Hematology Annual Meeting

2019-11-04 17:05:10 | Biotech ETFs in Focus on Impressive Q3 Earnings Results

2019-11-01 09:30:01 | Has Alexion Pharmaceuticals ALXN Outpaced Other Medical Stocks This Year?

2019-10-31 11:36:03 | The Zacks Analyst Blog Highlights: Alexion, Amgen, Gilead and AMAG

2019-10-31 09:30:01 | ALXN or CBM: Which Is the Better Value Stock Right Now?

2019-10-31 06:52:10 | Try Rising P/E Investing With 5 Top-Ranked Stocks

2019-10-31 06:30:00 | Dicerna ropes in Roche on gene-silencing deal worth up to $1.67B

2019-10-30 10:56:02 | Biotech Stock Roundup: Q3 Earnings Beat at ALXN & AMGN, Pipeline Updates & More

2019-10-30 10:43:57 | Healthcare ETFs Win in October: Here's Why

2019-10-30 06:29:26 | Should You Be Worried About Alexion Pharmaceuticals, Inc.'s NASDAQ:ALXN 14% Return On Equity?

2019-10-29 15:02:39 | SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations

2019-10-29 08:45:12 | Here is Why Growth Investors Should Buy Alexion ALXN Now

2019-10-28 11:59:03 | Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More

2019-10-28 11:18:33 | 3 ‘Perfect 10’ Biotech Stocks to Buy Amid Volatile Market Environment

2019-10-25 09:37:05 | 3 ‘Strong Buy’ Stocks Top Investors Are Buying

2019-10-24 11:09:03 | The Zacks Analyst Blog Highlights: Biogen, Vertex, Amgen, Alexion and Achillion Pharmaceuticals

2019-10-24 09:31:01 | Company News For Oct 24, 2019

2019-10-23 22:52:05 | Edited Transcript of ALXN earnings conference call or presentation 23-Oct-19 12:00pm GMT

2019-10-23 16:03:54 | Two Drugmakers Beat Earnings Forecasts — So Why Did One Topple?

2019-10-23 12:14:00 | The Dow Scratches Out a Gain as Investors Sort Through Earnings Jumble

2019-10-23 11:26:03 | Alexion ALXN Beats on Q3 Earnings, Lifts 2019 Guidance

2019-10-23 10:10:02 | Biotech ETFs Surge on a Flurry of Positive News

2019-10-23 09:58:00 | Alexion Stock Is Rising on an Earnings Beat, Better Guidance, Buybacks

2019-10-23 09:45:01 | Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates

2019-10-23 07:55:11 | Alexion Pharmaceuticals ALXN Q3 Earnings and Revenues Top Estimates

2019-10-23 06:56:00 | Alexion Rises After Drug Developer Beats Earnings Expectations

2019-10-23 06:30:00 | Alexion Reports Third Quarter 2019 Results

2019-10-23 06:00:00 | Alexion Pharmaceuticals, Inc. to Host Earnings Call

2019-10-23 02:32:00 | Alexion Earnings, Revenue Beat in Q3

2019-10-22 11:32:03 | Drug/Biotech Stock Q3 Earnings on Oct 23: LLY, ALXN & More

2019-10-22 10:18:02 | What's in Store for IDEXX Laboratories' IDXX Q3 Earnings?

2019-10-22 10:00:02 | What's in the Cards for Sarepta SRPT This Earnings Season?

2019-10-21 10:24:02 | Is Walgreens Boots WBA Likely to Disappoint in Q4 Earnings?

2019-10-21 09:33:01 | Alexion Gets FDA Approval for Label Expansion of Ultomiris

2019-10-18 20:25:08 | UPDATE 1-FDA approves Alexion's Ultomiris for another rare blood disease

2019-10-18 19:45:00 | Alexion Receives FDA Approval for ULTOMIRIS® ravulizumab-cwvz for Atypical Hemolytic Uremic Syndrome aHUS

2019-10-18 16:50:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.

2019-10-18 12:05:04 | Will Soliris Aid Growth for Alexion ALXN in Q3 Earnings?

2019-10-18 11:17:03 | Will Strong HIV Sales Drive Gilead's GILD Q3 Earnings?

2019-10-18 11:02:03 | What's in Store for Thermo Fisher TMO in Q3 Earnings?

2019-10-18 07:04:11 | Alexion to Buy Achillion for $930M, Strengthen PNH Franchise

2019-10-16 15:05:59 | Montco biotech firm sold for $930M, shares soar

2019-10-16 13:53:49 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Achillion Pharmaceuticals, Inc. to Alexion Pharmaceuticals, Inc. is Fair to Shareholders

2019-10-16 11:43:56 | Alexion makes $930M acquisition in bid to bolster blockbuster drug

2019-10-16 11:15:00 | Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion

2019-10-16 10:32:02 | Alexion Pharmaceuticals ALXN Earnings Expected to Grow: What to Know Ahead of Next Week's Release